Litigation Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
✉ Email this page to a colleague
CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
Docket | ⤷ Try a Trial | Date Filed | 2018-03-15 |
Court | District Court, D. New Jersey | Date Terminated | |
Cause | 15:1126 Patent Infringement | Assigned To | Susan Davis Wigenton |
Jury Demand | None | Referred To | Cathy L. Waldor |
Patents | 8,921,348; 9,829,495; 9,943,526 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC.
Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-10-23 | 31 | the holder of patent numbers 8,921,348 (the “’348 patent”), 9,829,495 (the “’495 patent”) and 9,943,526…9,943,526 (the “’526 patent”) (collectively, the “patents-in-suit”) and listed those patents in the Orange …process, applicants file “the patent number and the expiration date of any patent which claims the drug for…ANDAs must address patents that cover or might cover the relevant drugs. For each patent, companies can …Ex. A, B, C.) 1 The ‘348 patent was issued by the United States Patent and Trademark Office (“USPTO | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |